Exhibit 99.2 IPN 1087 Acquisition and Fusion’s Expanding Pipeline March 2021Exhibit 99.2 IPN 1087 Acquisition and Fusion’s Expanding Pipeline March 2021

Fusion – Next Generation TATs for Precision Oncology Targeted Alpha Therapies (TATs) deliver radiation directly to cancer PDAC Imaging cells using a precision medicine approach (theranostics) coronal ■ Fusion can create TATs from wide range of targeting molecules (antibodies, proteins, small molecules) We are expanding our pipeline by acquiring a small molecule that binds NTSR1; a validated cancer marker found on multiple cancer types notably pancreatic and colorectal cancers ■ Clinical imaging data show uptake of diagnostic form in pancreatic and CRC cancer patients ■ Preclinical therapy data with 225Ac (alpha emitter) show axial single dose tumor kill - high potency This first in class radiopharmaceutical augments our programs: ■ FPI-1434: Recently advanced from single- to multi-dosing Phase 1 ■ FPI-1966: Targeting Fibroblast Growth Factor Receptor 3 (FGFR3) ■ Recently signed long-term collaboration with AstraZeneca to develop Anterior Planar novel antibody-based TATs and combination therapies Liver Lesion and With deep radiopharmaceutical expertise, Fusion is positioned to lead Primary Tumor Uptake FPI-2059 through development 2Fusion – Next Generation TATs for Precision Oncology Targeted Alpha Therapies (TATs) deliver radiation directly to cancer PDAC Imaging cells using a precision medicine approach (theranostics) coronal ■ Fusion can create TATs from wide range of targeting molecules (antibodies, proteins, small molecules) We are expanding our pipeline by acquiring a small molecule that binds NTSR1; a validated cancer marker found on multiple cancer types notably pancreatic and colorectal cancers ■ Clinical imaging data show uptake of diagnostic form in pancreatic and CRC cancer patients ■ Preclinical therapy data with 225Ac (alpha emitter) show axial single dose tumor kill - high potency This first in class radiopharmaceutical augments our programs: ■ FPI-1434: Recently advanced from single- to multi-dosing Phase 1 ■ FPI-1966: Targeting Fibroblast Growth Factor Receptor 3 (FGFR3) ■ Recently signed long-term collaboration with AstraZeneca to develop Anterior Planar novel antibody-based TATs and combination therapies Liver Lesion and With deep radiopharmaceutical expertise, Fusion is positioned to lead Primary Tumor Uptake FPI-2059 through development 2

Fusion: Built As a Platform Company to Develop Multiple Classes of TATs Internal R&D Expertise Manufacturing and Supply Chain Expertise Ability and Experience Linking Alpha Emitting Isotopes to Radiopharmaceutical Manufacturing Different Classes of Targeting Molecules World-class GMP Manufacturing Antibody Small Molecule Hospitals and Clinics Leadership Position in Radiopharmaceuticals is Establishing Fusion as a Preferred Partner 3Fusion: Built As a Platform Company to Develop Multiple Classes of TATs Internal R&D Expertise Manufacturing and Supply Chain Expertise Ability and Experience Linking Alpha Emitting Isotopes to Radiopharmaceutical Manufacturing Different Classes of Targeting Molecules World-class GMP Manufacturing Antibody Small Molecule Hospitals and Clinics Leadership Position in Radiopharmaceuticals is Establishing Fusion as a Preferred Partner 3

Fusion’s Next Generation Radiopharmaceuticals for Precision Oncology Targeted TAT Binds to TAT Building Alpha the Target Blocks Therapy Tumor Cells (TAT) Actinium-225 Alpha-emitting Isotope Receptor The Chelate Proprietary Targeting Small Molecule As Carrier for Ac-225 4Fusion’s Next Generation Radiopharmaceuticals for Precision Oncology Targeted TAT Binds to TAT Building Alpha the Target Blocks Therapy Tumor Cells (TAT) Actinium-225 Alpha-emitting Isotope Receptor The Chelate Proprietary Targeting Small Molecule As Carrier for Ac-225 4

TATs: Multiple Mechanisms of Action Multiple Mechanisms of Action of a TAT TAT Binds to the 1) Multiple lethal 2) Bystander 3) Potential Target Receptor double-stranded effect vaccine effect Tumor Cells Tumor DNA breaks Localized TAT Bystander Primary Cell Death Cell Ac-225 α Death decay Particles CD8+ yields T cells 4 alpha particles Alpha-Emitters’ Multiple Mechanisms Show Enhanced Killing of Tumor Cells 5TATs: Multiple Mechanisms of Action Multiple Mechanisms of Action of a TAT TAT Binds to the 1) Multiple lethal 2) Bystander 3) Potential Target Receptor double-stranded effect vaccine effect Tumor Cells Tumor DNA breaks Localized TAT Bystander Primary Cell Death Cell Ac-225 α Death decay Particles CD8+ yields T cells 4 alpha particles Alpha-Emitters’ Multiple Mechanisms Show Enhanced Killing of Tumor Cells 5

IPN-1087 - A Validated Targeted Theranostic for the Neurotensin Receptor 1 (NTSR1) Imaging Shows Targeted Uptake In: NTSR1 is an attractive oncology target CRC and PDAC patients ■ Validated cancer biomarker associated with carcinogenesis of several types of solid tumors ■ High expression, similar to SSTR2 in NETs, which ® Lutathera targets IPN-1087 is a small molecule capable of delivering theranostic radiometals to NTSR1 expressing tumors Colorectal Carcinoma Pancreatic Ductal Adenocarcinoma ■ Imaging studies with IPN-1087 confirm tumor uptake in patients with colorectal, pancreatic, gastric cancers (primary and metastatic sites) ■ Dosimetry based on the imaging shows that IPN-1087 can be an effective delivery vehicle for targeting alpha emitters to NTSR1 expressing tumors 6IPN-1087 - A Validated Targeted Theranostic for the Neurotensin Receptor 1 (NTSR1) Imaging Shows Targeted Uptake In: NTSR1 is an attractive oncology target CRC and PDAC patients ■ Validated cancer biomarker associated with carcinogenesis of several types of solid tumors ■ High expression, similar to SSTR2 in NETs, which ® Lutathera targets IPN-1087 is a small molecule capable of delivering theranostic radiometals to NTSR1 expressing tumors Colorectal Carcinoma Pancreatic Ductal Adenocarcinoma ■ Imaging studies with IPN-1087 confirm tumor uptake in patients with colorectal, pancreatic, gastric cancers (primary and metastatic sites) ■ Dosimetry based on the imaging shows that IPN-1087 can be an effective delivery vehicle for targeting alpha emitters to NTSR1 expressing tumors 6

FPI-2059 - A Novel Small Molecule TAT Pancreatic Ductal Adenocarcinoma 225 Ac IPN 1087 Shows Single Dose Tumor IPN-1087 proven ability to deliver Kill In Preclinical Models radiometals to tumors in multiple cancer types makes it a promising candidate for 225 targeted alpha therapy with Ac 225 Preclinical data with Ac labeled IPN-1087 show single dose tumor kill Fusion will leverage its expertise to quickly 225 move the Ac labeled IPN-1087 (FPI-2059) into clinical development 7 Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights ReservedFPI-2059 - A Novel Small Molecule TAT Pancreatic Ductal Adenocarcinoma 225 Ac IPN 1087 Shows Single Dose Tumor IPN-1087 proven ability to deliver Kill In Preclinical Models radiometals to tumors in multiple cancer types makes it a promising candidate for 225 targeted alpha therapy with Ac 225 Preclinical data with Ac labeled IPN-1087 show single dose tumor kill Fusion will leverage its expertise to quickly 225 move the Ac labeled IPN-1087 (FPI-2059) into clinical development 7 Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights Reserved

FPI-2059 Development Strategy and Timeline 2021 1H 2022 Rapid development of IPN- 225 1087 as an Ac-labeled TAT IND Filing Cohort Expansion Accelerated completion Opportunity of requisite preclinical studies Leverage FPI-1434 225 with Ac labeled IPN-1087 Imaging has shown experience to submit IND (FPI-2059) to enable regulatory uptake in multiple for Phase 1 dose escalation filings cancers: studies (including multi- dosing) ■ Gastric Expedited set-up of ■ Pancreatic Increase PoS through clinical supply ■ Colorectal inclusion of theranostic Parallel development of imaging to identify NTSR1 manufacturing; validation positive patients NTSR1 is expressed 225 of Ac GMP production for in multiple other Open trial sites clinical supply tumor types, such as prostate 8 Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights ReservedFPI-2059 Development Strategy and Timeline 2021 1H 2022 Rapid development of IPN- 225 1087 as an Ac-labeled TAT IND Filing Cohort Expansion Accelerated completion Opportunity of requisite preclinical studies Leverage FPI-1434 225 with Ac labeled IPN-1087 Imaging has shown experience to submit IND (FPI-2059) to enable regulatory uptake in multiple for Phase 1 dose escalation filings cancers: studies (including multi- dosing) ■ Gastric Expedited set-up of ■ Pancreatic Increase PoS through clinical supply ■ Colorectal inclusion of theranostic Parallel development of imaging to identify NTSR1 manufacturing; validation positive patients NTSR1 is expressed 225 of Ac GMP production for in multiple other Open trial sites clinical supply tumor types, such as prostate 8 Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights Reserved

FPI-2059 Multiple Market Opportunities Pancreatic Cancer (PDAC) Colorectal Cancer (CRC) Prostate Cancer 1 58K new patients annually (US+EU5) Opportunities to improve current SoC Radiopharmaceuticals are across all lines of metastatic disease showing increasing utility Typically treated with surgery, chemo ® (Xofigo , PSMA-617) rd 4 or radiation, depending on stage and 3 most common cancer globally tumor type High unmet medical need nd 4 2 most common cancer death for metastatic prostate ≈$2B peak net sales opportunity in 5 ≈$10B large and stable market cancer with neuroendocrine 2 first-line PDAC (US+EU5) differentiation ■ Patients that are NTSR1 Gastric Cancer positive but androgen and PSMA receptor negative ~26k estimated new diagnoses in the 3 US annually 4 32% survival rate +5 years FPI-2059 1. Blended average US EPIC Epidemiology & Kantar, EU Kantar 2019. 2.. Decision Resources Group 2019 report; 3. American Cancer Society https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html; 4. Based on data from SEER 18 2010–2016 (https://seer.cancer.gov/statfacts/html/stomach.html); 5. DRG report, including US, EU5 and Japan; 6. Decision Resources Group report, including US, EU5 and Japan 9FPI-2059 Multiple Market Opportunities Pancreatic Cancer (PDAC) Colorectal Cancer (CRC) Prostate Cancer 1 58K new patients annually (US+EU5) Opportunities to improve current SoC Radiopharmaceuticals are across all lines of metastatic disease showing increasing utility Typically treated with surgery, chemo ® (Xofigo , PSMA-617) rd 4 or radiation, depending on stage and 3 most common cancer globally tumor type High unmet medical need nd 4 2 most common cancer death for metastatic prostate ≈$2B peak net sales opportunity in 5 ≈$10B large and stable market cancer with neuroendocrine 2 first-line PDAC (US+EU5) differentiation ■ Patients that are NTSR1 Gastric Cancer positive but androgen and PSMA receptor negative ~26k estimated new diagnoses in the 3 US annually 4 32% survival rate +5 years FPI-2059 1. Blended average US EPIC Epidemiology & Kantar, EU Kantar 2019. 2.. Decision Resources Group 2019 report; 3. American Cancer Society https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html; 4. Based on data from SEER 18 2010–2016 (https://seer.cancer.gov/statfacts/html/stomach.html); 5. DRG report, including US, EU5 and Japan; 6. Decision Resources Group report, including US, EU5 and Japan 9

Deal Terms Fusion will issue to Ipsen: ■ 400,000 shares of its common stock upon closing ■ 200,000 shares upon a patent-related milestone Fusion will pay up to €67.5 million upon the achievement of certain development and regulatory milestones; low single digit royalties on potential future net sales; and up to €350 million in sales milestones Fusion will be responsible for up to a total of €70 million in development milestone payments for up to three indications and mid-single to low-double-digit royalties on potential future net sales to a third-partyDeal Terms Fusion will issue to Ipsen: ■ 400,000 shares of its common stock upon closing ■ 200,000 shares upon a patent-related milestone Fusion will pay up to €67.5 million upon the achievement of certain development and regulatory milestones; low single digit royalties on potential future net sales; and up to €350 million in sales milestones Fusion will be responsible for up to a total of €70 million in development milestone payments for up to three indications and mid-single to low-double-digit royalties on potential future net sales to a third-party

IPN-1087 Enhances Fusion’s Growing Pipeline of TATs Early Radiopharma Preclinical Fusion Programs Phase 1 Phase 2 Phase 3 Discovery Optimization Development FPI-1434 Solid Tumors Expressing IGF-1R FPI-1966 Head & Neck and Bladder Cancers Expressing FGFR3 FPI-2059 (IPN-1087) Solid Tumors Expressing NTSR1 FPI-1434 Combination Solid Tumors Expressing IGF-1R Solid Tumor Early Pipeline Solid Tumor Targets not disclosed Solid Tumor Early Radiopharma Preclinical Partnered Programs Phase 1 Phase 2 Phase 3 Discovery Optimization Development AZ Novel TATs (Up to 3) Targets not disclosed AZ Combinations (Up to 5) Target not disclosedIPN-1087 Enhances Fusion’s Growing Pipeline of TATs Early Radiopharma Preclinical Fusion Programs Phase 1 Phase 2 Phase 3 Discovery Optimization Development FPI-1434 Solid Tumors Expressing IGF-1R FPI-1966 Head & Neck and Bladder Cancers Expressing FGFR3 FPI-2059 (IPN-1087) Solid Tumors Expressing NTSR1 FPI-1434 Combination Solid Tumors Expressing IGF-1R Solid Tumor Early Pipeline Solid Tumor Targets not disclosed Solid Tumor Early Radiopharma Preclinical Partnered Programs Phase 1 Phase 2 Phase 3 Discovery Optimization Development AZ Novel TATs (Up to 3) Targets not disclosed AZ Combinations (Up to 5) Target not disclosed

Thank You www.FusionPharma.com Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights ReservedThank You www.FusionPharma.com Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights Reserved